Eighteen nucleic acid therapeutics have been approved for treatment of various diseases in
the last 25 years. Their modes of action include antisense oligonucleotides (ASOs), splice …

The past decade has witnessed ongoing progress in precision medicine to improve human
health. As an emerging diagnostic technique, liquid biopsy can provide real-time …

Oligonucleotides can be used to modulate gene expression via a range of processes
including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation …

The introduction of the in vitro evolution method known as SELEX (systematic evolution of
ligands by exponential enrichment) more than 30 years ago led to the conception of …

Aptamers are oligonucleotide sequences with a length of about 25–80 bases which have
abilities to bind to specific target molecules that rival those of monoclonal antibodies. They …

Nucleic acid aptamers, often termed'chemical antibodies', are functionally comparable to
traditional antibodies, but offer several advantages, including their relatively small physical …

Aptamers are nucleic acid molecules that mimic antibodies by folding into complex 3D
shapes that bind to specific targets. Although some aptamers exist naturally as the ligand …

Precision medicine holds great promise to harness genetic and epigenetic cues for targeted
treatment of a variety of diseases, ranging from many types of cancers, neurodegenerative …

Aptamers are short single-stranded DNA or RNA oligonucleotides that can selectively bind
to small molecular ligands or protein targets with high affinity and specificity, by acquiring …

Aptamers are short, single-stranded oligonucleotides that bind to specific target molecules.
The shape-forming feature of single-stranded oligonucleotides provides high affinity and …